Nir Uriel, MD
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1578716478
Payments from drug & device makers
Across 623 payments — averaging $1419.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$612K
- Novartis$210K
- Abiomed$32K
- Medtronic$19K
- Transmedics, Inc.$3K
- Merck$2K
- plus $8K from 29 others
Across 4 payments — averaging $18,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$72K
What the payments were for
- Consulting fees$4,2143%
- Speaking & faculty fees$3000%
- Travel & lodging$87,56770%
- Food & beverage$32,74326%
- Education$180%
- Gifts$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 447 | $612,011 |
| Novartis | 9 | $209,671 |
| Abiomed | 46 | $31,769 |
| Medtronic | 23 | $18,520 |
| Transmedics, Inc. | 5 | $2,504 |
| Merck | 18 | $2,061 |
| Itamar Medical Inc | 5 | $1,657 |
| Ancora Heart, Inc. | 5 | $1,411 |
| Cvrx, Inc. | 9 | $1,027 |
| Impulse Dynamics (USA) Inc. | 7 | $1,008 |
| Paragonix Technologies, Inc. | 2 | $571 |
| Opsens Inc. | 2 | $283 |
| Edwards Lifesciences | 3 | $268 |
| Procyrion, Inc. | 3 | $204 |
| AstraZeneca | 7 | $117 |
| Elutia, Inc. | 1 | $117 |
| Endotronix, Inc. | 1 | $108 |
| Regeneron | 1 | $97 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $91 |
| Scpharmaceuticals Inc. | 3 | $80 |
| Xvivo Perfusion Inc. | 1 | $70 |
| Boehringer Ingelheim | 4 | $67 |
| Amgen | 3 | $55 |
| Livanova USA, Inc. | 1 | $42 |
| United Therapeutics Corporation | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $36 |
| Vifor Pharma, Inc. | 1 | $33 |
| Portola Pharmaceuticals, LLC | 1 | $27 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Nihon Kohden America, LLC | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$21,163
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$20,502
- MitraClip$14,515
- CARDIOMEMS$11,375
- ENSITE$11,280
- HeartMate 3 Left Ventricular Assist Device$4,078
- HeartMate 3 Left Ventricular Dev$2,975
- ORGAN CARE SYSTEM$2,504
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$1,565
- AccuCinch$1,411
- THORATEC HEARTMATE II, LVAS IMPLANT KIT$1,401
- VERQUVO$1,246
- HeartWare HVAD$985
- HeartMate$937
- Barostim Neo System$870
- WatchPat$866
- WatchPATONE$791
- OPTIMIZER SMART SYSTEM$689
- Paragonix SherpaPak Cardiac Transport System$646
- HeartMate Touch$554
How this compares
$884,068 in reported general payments places this provider in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 31 | $42,233 |
| EntrestoSacubitril/Valsartan | 18 | $20,931 |
| FarxigaDapagliflozin Propanediol | 11 | $13,862 |
| EliquisApixaban | 18 | $13,592 |
| Repatha SureclickEvolocumab | 11 | $10,124 |
| Eplerenone | 16 | $1,921 |
| Atorvastatin Calcium | 16 | $218 |
| Metoprolol Succinate | 11 | $89 |
| Spironolactone | 13 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $67 | $42,23331 claims |
| NovartisEntresto | $209,671 | $20,93118 claims |
| AstraZenecaFarxiga | $117 | $13,86211 claims |
| PfizerEliquis | $12 | $13,59218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Mathew MaurerNew York$5M
- Evelyn HornNew York$2.9M
- Johanna ContrerasNew York$1.4M
- Parag GoyalNew York$1.1M
- Tajinderpal SaraonNew York$618K
- Kelly AxsomNew York$502K
- Sean PinneyNew York$414K
- Yevgeniy BrailovskyNew York$339K
- James YoussefNew York$287K
- Alex ReyentovichNew York$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.